IMMUNOGEN
ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, includi... ng multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.
IMMUNOGEN
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
1981-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.immunogen.com
Total Employee:
501+
Status:
Active
Contact:
781-895-0600
Total Funding:
55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
International Cardio Corporation
ICC engages in the research and development of high intensity-focused ultrasound solutions to treat peripheral artery diseases.
Merus
Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Eli Lilly
Eli Lilly investment in Post-IPO Equity - ImmunoGen
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-16 | ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer |
Official Site Inspections
http://www.immunogen.com Semrush global rank: 1.72 M Semrush visits lastest month: 13.93 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
